Member Info for Amonk84

https://www.pdsbiotech.com/images/presentation/PDS_Biotech_Corporate_Presentation_AUGUST2020.pdf

SK, there is that risk of course but there will be also be quite a few who came here on the covid wave and will jump now knowing that's going nowhere until Q1 2021 was it?
I'm not worried too much as I'm invested here not trading it. Bottom draw for 12 months.

Usain, announce what at the same time?

RD I have that same concern. At the point of demerger our value oof Tiziana will drop as we've removed Stem and then the possibility of a massive dilution.

The time lines are going to shake alot of traders out tomorrow.
>Stem weeks away from cut off,
>phase two trials in Q1-Q2 2021
I believe the share value increase of late has been in anticipation of the Stem demerger and now knowing you can sell tomorrow with your significant profits and trade for a few weeks and come back in at a similar price or lower means there's going to be a sell off tomorrow.
Investers will just sit tight and reap their rewards in 12 months but will be interesting to see what happens in the am.

Agreed.
I can sell as much as I want but can't buy anything above £40K.
MM's are loading up, we could even see 7 for a brief dip to catch some more stops.
I definitely expect another rns this week before the webinar.

Hopefully

Dr. David Sidransky - A director of Orgenesis and a director of ImClone Systems, Inc., a global biopharmaceutical company until it's merger with...... Eli Lilly.

Dr. David Sidransky - A director of Orgenesis...

Dr. Sidransky has served as a director since his appointment on July 18, 2013. Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division at Johns Hopkins University School of Medicine's Department of Otolaryngology and Professor of Oncology, Cellular & Molecular Medicine, Urology, Genetics, and Pathology at the John Hopkins University School of Medicine. Dr. Sidransky is one of the most highly cited researchers in clinical and medical journals in the world in the field of oncology during the past decade, with over 460 peer reviewed publications. Dr. Sidransky is a founder of a number of biotechnology companies and holds numerous biotechnology patents. Dr. Sidransky has served as Vice Chairman of the board of directors, and was, until the merger with Eli Lilly, a director of ImClone Systems, Inc., a global biopharmaceutical company committed to advancing oncology care. He is serving, or has served on, the scientific advisory boards of MedImmune, LLC, Roche, Amgen Inc. and Veridex, LLC (a Johnson & Johnson diagnostic company),

I've either painted a monet with my connecting dots or a Picasso. Either one, I feel, has massive value.

Thanks Pingu. I'm trying to locate my older postings on orgenesis, to no avail.

Apologies, heading automatically pasted.

https://ir.orgenesis.com/press-releases/detail/161

MM's must be expecting a lot of action. As level 2 is stacked more than I've seen it before.

Hold on to your butt's!

Interesting. Thanks TT

Tiziana life sciences are demerging StemprintER with a UK listing and Motif needs a RTO.
Can anyone give an indication of what it would cost TILS to get Stem listed through MTFB?

What are the chances of TILS using Motif Bio to float StemprintER?

Thanks. I meant a limit order and I think its just limited to the mobile app, no problem placing a limit order on the website.

Anyone know why there is no option to place an order on the exchange through IG?

The late reported buys from yesterday pop up before market open today.

Huge buys.